|
Miltenyi Biotec
granzyme b apc rea226 Granzyme B Apc Rea226, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/Granzyme+B+Antibody%2C+anti-human%2Fmouse%2Frat%2C+REAfinity/pm42843925-108-50-56 Average 95 stars, based on 1 article reviews
granzyme b apc rea226 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
mouse granzyme b elisa kit ![]() Mouse Granzyme B Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/Mouse+GzmB+(Granzyme+B)+ELISA+Kit/pmc13682500-84-68-74 Average 95 stars, based on 1 article reviews
mouse granzyme b elisa kit - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
human granzyme b elisa kit ![]() Human Granzyme B Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/Human+GzmB+(Granzyme+B)+ELISA+Kit/pmc13682500-84-41-47 Average 94 stars, based on 1 article reviews
human granzyme b elisa kit - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Boster Bio
granzyme b kit ![]() Granzyme B Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/Mouse+Granzyme+B+ELISA+Kit+PicoKine/pm42860508-350-25-29 Average 90 stars, based on 1 article reviews
granzyme b kit - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Proteintech
mouse anti human granzyme b monoclonal antibody ![]() Mouse Anti Human Granzyme B Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/GZMB+Antibody/pmc13680154-78-14-21 Average 95 stars, based on 1 article reviews
mouse anti human granzyme b monoclonal antibody - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Proteintech
granzyme b ![]() Granzyme B, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/GZMB+Antibody/pmc13626062-446-5-8 Average 95 stars, based on 1 article reviews
granzyme b - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Boster Bio
granzyme b elisa kit ![]() Granzyme B Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/Anti-Granzyme+B+GZMB+Antibody/10__1016_slash_j__apsb__2026__09__030-125-14-18 Average 90 stars, based on 1 article reviews
granzyme b elisa kit - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
gzmb ![]() Gzmb, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/Granzyme+B+Antibody%2C+anti-human%2Fmouse%2Frat%2C+REAfinity/pm42816581-281-17-19 Average 95 stars, based on 1 article reviews
gzmb - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Cellular Technology Ltd
three color fluorospot assay ![]() Three Color Fluorospot Assay, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/Human+IFN-%CE%B3+IL-2+Granzyme+B+Three-Color+FluoroSpot/10__3390_slash_biomedicines14102147-162-17-20 Average 99 stars, based on 1 article reviews
three color fluorospot assay - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
Proteintech
anti granzyme b ![]() Anti Granzyme B, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/granzyme+b/GZMB+Antibody/10__1016_slash_j__gendis__2026__102497-90-40-43 Average 95 stars, based on 1 article reviews
anti granzyme b - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) ELISA detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience),
Techniques: Migration, Analysis, Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Flow Cytometry, Transwell Assay, Comparison, X-Ray Photoelectron Spectroscopy
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: TAMCs recruit Tregs into the tumor microenvironment by secreting chemokines. (A) ELISA detection of CCL1, CCL5, CCL17, CCL22, and CCL28 secretion by TAMCs (after subtracting CCL1, CCL5, CCL17, CCL22, and CCL28 levels in TCCS); (B) ELISA detection of CCL17 levels in tumor tissues and adjacent tissues; (C) Correlation analysis between TAMCs and CCL17 concentration; D: Correlation analysis between Tregs and CCL17 concentration; (E, F) Transwell migration assay to assess Treg migration capacity. Data are presented as mean ± SD. (A, B), independent samples t ‐tests ( N = 3); (C, D) Spearman 's rank correlation analysis ( n = 59); (F), one‐way ANOVA and Tukey's multiple comparison test ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience),
Techniques: Enzyme-linked Immunosorbent Assay, Analysis, Concentration Assay, Transwell Migration Assay, Migration, Comparison
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: The TAMCs‐Tregs axis inhibits CD8 + T cell function. (A, B) Flow cytometry analysis of Treg‐mediated suppression of CD8 + T cell proliferation; (C–F) ELISA for Granzyme B, IFN‐γ, TNF‐α, and Perforin in supernatants from CD8 + T cell proliferation assays. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience),
Techniques: Cell Function Assay, Flow Cytometry, Analysis, Enzyme-linked Immunosorbent Assay, Comparison
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: Combination therapy of anti‐PD‐1 antibody and CCR4 antagonists reshapes the tumor immune microenvironment in HCC. (A–F) Flow cytometry analysis of immune cell proportions (MCs, Tregs, CD8 + T cells) in tumor tissue; G–K: ELISA detection of Granzyme B, IFN‐γ, TNF‐α, Perforin, and CCL17 levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience),
Techniques: Flow Cytometry, Analysis, Immune Cell, Tissue, Enzyme-linked Immunosorbent Assay, Comparison
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: Validation of the synergistic antitumor efficacy of the triple‐drug therapy in an in situ Hepa1‐6 HCC model. (A) Representative images of in situ tumors; (B): Tumor volume in each group; (C) Tumor weight in each group; (D) Average ratio of liver weight to body weight; (E, F): Ki67 immunohistochemical staining and quantitative analysis; (G–L) Flow cytometry detection of the proportions of various immune cells (mast cells, Tregs, CD8 + T cells); (M) ELISA detection of Granzyme B, IFN‐γ, TNF‐α, and perforin levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6).
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience),
Techniques: Biomarker Discovery, In Situ, Immunohistochemical staining, Staining, Analysis, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Comparison
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) ELISA detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam),
Techniques: Migration, Analysis, Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Flow Cytometry, Transwell Assay, Comparison, X-Ray Photoelectron Spectroscopy
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: TAMCs recruit Tregs into the tumor microenvironment by secreting chemokines. (A) ELISA detection of CCL1, CCL5, CCL17, CCL22, and CCL28 secretion by TAMCs (after subtracting CCL1, CCL5, CCL17, CCL22, and CCL28 levels in TCCS); (B) ELISA detection of CCL17 levels in tumor tissues and adjacent tissues; (C) Correlation analysis between TAMCs and CCL17 concentration; D: Correlation analysis between Tregs and CCL17 concentration; (E, F) Transwell migration assay to assess Treg migration capacity. Data are presented as mean ± SD. (A, B), independent samples t ‐tests ( N = 3); (C, D) Spearman 's rank correlation analysis ( n = 59); (F), one‐way ANOVA and Tukey's multiple comparison test ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam),
Techniques: Enzyme-linked Immunosorbent Assay, Analysis, Concentration Assay, Transwell Migration Assay, Migration, Comparison
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: The TAMCs‐Tregs axis inhibits CD8 + T cell function. (A, B) Flow cytometry analysis of Treg‐mediated suppression of CD8 + T cell proliferation; (C–F) ELISA for Granzyme B, IFN‐γ, TNF‐α, and Perforin in supernatants from CD8 + T cell proliferation assays. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam),
Techniques: Cell Function Assay, Flow Cytometry, Analysis, Enzyme-linked Immunosorbent Assay, Comparison
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: Combination therapy of anti‐PD‐1 antibody and CCR4 antagonists reshapes the tumor immune microenvironment in HCC. (A–F) Flow cytometry analysis of immune cell proportions (MCs, Tregs, CD8 + T cells) in tumor tissue; G–K: ELISA detection of Granzyme B, IFN‐γ, TNF‐α, Perforin, and CCL17 levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam),
Techniques: Flow Cytometry, Analysis, Immune Cell, Tissue, Enzyme-linked Immunosorbent Assay, Comparison
Journal: Journal of Biochemical and Molecular Toxicology
Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment
doi: 10.1002/jbt.71127
Figure Lengend Snippet: Validation of the synergistic antitumor efficacy of the triple‐drug therapy in an in situ Hepa1‐6 HCC model. (A) Representative images of in situ tumors; (B): Tumor volume in each group; (C) Tumor weight in each group; (D) Average ratio of liver weight to body weight; (E, F): Ki67 immunohistochemical staining and quantitative analysis; (G–L) Flow cytometry detection of the proportions of various immune cells (mast cells, Tregs, CD8 + T cells); (M) ELISA detection of Granzyme B, IFN‐γ, TNF‐α, and perforin levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6).
Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam),
Techniques: Biomarker Discovery, In Situ, Immunohistochemical staining, Staining, Analysis, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Comparison
Journal: Frontiers in Immunology
Article Title: Metabolic reprogramming of NK cells in chronic brucellar arthritis: role of the HIF-1α/mTOR axis
doi: 10.3389/fimmu.2026.1961240
Figure Lengend Snippet: Peripheral blood NK cell functional inhibition in brucellar arthritis correlates with HIF-1α/mTOR pathway suppression. (A, B) Flow cytometric analysis of the proportion of CD3 - CD56 + NK cells in peripheral blood from each group (healthy controls, HC; acute-phase, A-BA; chronic-phase, C-BA). Compared with HC, the proportion of NK cells was increased in both acute- and chronic-phase patients. Flow cytometry also detected IFN-γ production and degranulation function (CD107a positivity) of NK cells in each group. NK cells from chronic-phase patients exhibited significantly lower IFN-γ and CD107a expression levels than those from acute-phase patients. (C) Expression levels of HIF-1α and Granzyme B in synovial tissues from each group. Chronic-phase patients showed elevated HIF-1α and reduced Granzyme (B) (D) Western blot analysis of HIF-1α protein expression in patients from each group. HIF-1α protein bands were markedly enhanced in chronic-phase patients. (E, F) Western blot detection of phosphorylation levels of the PI3K/AKT/mTOR pathway (p-PI3K, p-AKT, p-mTOR) and total mTOR in NK cells from each group. Compared with HC, chronic-phase patients had significantly reduced levels of p-PI3K, p-AKT, and p-mTOR. (G) Relative mRNA expression levels of Granzyme B, IFN-γ, and HIF-1α in NK cells from each group (qPCR results).Data are presented as mean ± SD (n=3 per group for Western blot/qPCR, n=20 per group for flow cytometry, or at least 3 independent experiments). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. Statistical methods: one‐way ANOVA with Tukey’s post‐hoc test (after Shapiro‐Wilk normality check) or Student’s t‐test as appropriate; for multiple comparisons, P values were adjusted using the Benjamini‐Hochberg method.
Article Snippet: Add rabbit anti human HIF-1 α monoclonal antibody (Abcam, ab228649, dilution ratio 1:200) and
Techniques: Functional Assay, Inhibition, Analysis, Flow Cytometry, Expressing, Western Blot, Phospho-proteomics
Journal: Frontiers in Immunology
Article Title: Metabolic reprogramming of NK cells in chronic brucellar arthritis: role of the HIF-1α/mTOR axis
doi: 10.3389/fimmu.2026.1961240
Figure Lengend Snippet: Serum cytokine profiles in healthy controls and brucellar arthritis patients at different disease phases. (A, B) Concentrations (pg/mL) of IFN-γ, TNF-α, Granzyme B, IL-10, IL-13, and IL-18 in serum from healthy controls (HC), acute-phase (A-BA), and chronic-phase (C-BA) patients. Data are presented as mean or range (n=20 per group). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. Statistical methods: one-way ANOVA with Tukey’s post-hoc test (after normality check) or Kruskal-Wallis test as appropriate; for multiple comparisons, P values were adjusted using the Benjamini-Hochberg method.
Article Snippet: Add rabbit anti human HIF-1 α monoclonal antibody (Abcam, ab228649, dilution ratio 1:200) and
Techniques:
Journal: Frontiers in Immunology
Article Title: Metabolic reprogramming of NK cells in chronic brucellar arthritis: role of the HIF-1α/mTOR axis
doi: 10.3389/fimmu.2026.1961240
Figure Lengend Snippet: HIF‐1α knockout restores mTOR pathway activity, mitochondrial respiration, glycolysis, and effector molecule expression in NK‐92 cells after HKBA treatment. Wild‐type (WT) NK‐92 cells and HIF‐1α‐knockout (KO) NK‐92 cells were treated with HKBA (MOI = 100) for 72 h, or left untreated as controls. (A) Western blot analysis of phosphorylation levels of the PI3K/AKT/mTOR signaling pathway and downstream effector molecules in each group. (B) Quantitative analysis of the ratios of phosphorylated proteins to total proteins (fold change). (C) Oxygen consumption rate (OCR) measured by Seahorse XFe96 metabolic analyzer, reflecting mitochondrial oxidative phosphorylation function. OCR was measured in real time after sequential injection of oligomycin (1 μmol/L), FCCP (1 μmol/L), and rotenone/antimycin A (ROT/AA, 0.5 μmol/L). (D) Quantitative analysis of OCR parameters based on (C) . Data are presented as OCR (pmol/min), mean ± SD (n=3). (E) Extracellular acidification rate (ECAR) measured by Seahorse XFe96, reflecting glycolytic activity. ECAR was measured in real time after sequential injection of glucose (10 mmol/L),oligomycin(1μmol/L),and2‐deoxy‐D‐glucose(2‐DG, 50 mmol/L). (F) Quantitative analysis of ECAR parameters based on (E) . Data are presented as ECAR (mpH/min), mean ± SD (n=3). (G) Detection of IFN‐γ and Granzyme B secretion capacity by PCR. (H) Representative JC‐1 fluorescence images of NK cells in each group, showing JC‐1 red aggregate channel, green monomer channel, and merged fluorescence images. (I) Quantitative analysis of the JC‐1 red/green fluorescence ratio, reflecting mitochondrial membrane potential levels in each group. Data are presented as mean ± SD, and were repeated in three independent experiments. All comparisons were performed using one‐way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant (P > 0.05).
Article Snippet: Add rabbit anti human HIF-1 α monoclonal antibody (Abcam, ab228649, dilution ratio 1:200) and
Techniques: Knock-Out, Activity Assay, Expressing, Western Blot, Analysis, Phospho-proteomics, Injection, Fluorescence, Membrane
Journal: Frontiers in Immunology
Article Title: Metabolic reprogramming of NK cells in chronic brucellar arthritis: role of the HIF-1α/mTOR axis
doi: 10.3389/fimmu.2026.1961240
Figure Lengend Snippet: mTOR inhibitor rapamycin completely blocks the restorative effects of HIF-1α knockout on NK cell metabolism and function. Wild-type (WT) NK-92 cells and HIF-1α-knockout (KO) NK-92 cells were treated with HKBA (MOI = 100) for 72 h, or left untreated as controls. In some experimental groups, cells were pretreated with the mTOR pathway inhibitor rapamycin (100 nM) for 1 h before HKBA addition. (A) Western blot analysis of phosphorylation levels of the PI3K/AKT/mTOR signaling pathway and downstream effector molecules in each group. (B) Quantitative analysis of the ratios of phosphorylated proteins to total proteins (fold change). (C) Oxygen consumption rate (OCR) measured by Seahorse XFe96 metabolic analyzer, reflecting mitochondrial oxidative phosphorylation function. OCR was measured in real time after sequential injection of oligomycin (1 μmol/L), FCCP (1 μmol/L), and rotenone/antimycin A (ROT/AA, 0.5 μmol/L). (D) Quantitative analysis of OCR parameters based on (C) . Data are presented as OCR (pmol/min), mean ± SD (n=3). (E) Extracellular acidification rate (ECAR) measured by Seahorse XFe96, reflecting glycolytic activity. ECAR was measured in real time after sequential injection of glucose (10 mmol/L), oligomycin (1 μmol/L), and 2-deoxy-D-glucose (2-DG, 50 mmol/L). (F) Quantitative analysis of ECAR parameters based on (E) . Data are presented as ECAR (mpH/min), mean ± SD (n=3). (G) Detection of IFN-γ and Granzyme B secretion capacity by PCR. (H) Representative JC-1 fluorescence images of NK cells in each group, showing JC-1 red aggregate channel, green monomer channel, and merged fluorescence images. (I) Quantitative analysis of the JC-1 red/green fluorescence ratio, reflecting mitochondrial membrane potential levels in each group. Data are presented as mean ± SD, and were repeated in three independent experiments. All comparisons were performed using one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant (P > 0.05).
Article Snippet: Add rabbit anti human HIF-1 α monoclonal antibody (Abcam, ab228649, dilution ratio 1:200) and
Techniques: Knock-Out, Western Blot, Analysis, Phospho-proteomics, Injection, Activity Assay, Fluorescence, Membrane